Mgoes recaps slides from a Harvard longevity conference, also noting Novartis has an aging diseases department and CDER plans to list aging as a priority.
Recap by typeshit. Post by Mgoes (bio/acc 🤖💉) on X.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
10:45
The nutrition and exercise graduate walks through her food picks for people on retatrutide, aimed at holding onto muscle during weight loss.
Inc. reports that some Georgia clinics are still marketing an unapproved Lilly weight loss drug even as the company moves against its sale.
Loading…